
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is a logistics company that is making significant strides in the life sciences industry, with strong revenue growth and new facilities in its Life Sciences Services division. Its upcoming launch in Paris is expected to further contribute to its growth. With a promising outlook for the future and a growing portfolio of commercial therapies, CryoPort is well-positioned to take advantage of the rapidly expanding cell and gene therapy market. Additionally, the company's successful second quarter was driven by positive momentum in key areas, such as the expansion of its BioLogistics services and growth in commercial therapy volumes. With positive EBITDA and revenue growth and a specialized equipment strategy, CryoPort presents a promising investment opportunity that aligns with the growing trends of cell and gene therapy commercialization and globalization of supply chains.
Bears say
CryoPort is facing slowing growth in its Life Sciences Products segment, which generates around 45% of its revenue, and is heavily reliant on its MVE Biological Solutions division. Despite its upcoming CryoVerse Ecosystem and the deployment of AI, these initiatives may not immediately reflect in financials and labor intensiveness could impede operating leverage. Even with potential upside drivers, the company will continue to face challenges in scaling its service platform without proportionate headcount additions.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares